Related Experiment Videos
[New treatments in dementia]
1Servicio de Neurología, Hospital Virgen del Camino, Pamplona. jmanubens@unav.es
Neurologia (Barcelona, Spain)
|February 5, 2000
Summary
This review covers Alzheimer's disease treatments, focusing on cholinesterase inhibitors and their clinical use. Emerging research in Abeta-42 immunization suggests novel etiopathogenic treatment avenues.
Area of Science:
- Neurology
- Pharmacology
Context:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Current AD treatments primarily manage symptoms, not halt progression.
Purpose:
- To review advances in Alzheimer's disease treatment.
- To discuss the application of cholinesterase inhibitors in clinical practice and studies.
- To highlight emerging etiopathogenic treatment strategies.
Summary:
- Reviews current Alzheimer's disease treatments, emphasizing cholinesterase inhibitors like tacrine, donepezil, and rivastigmine.
- Examines the methodologies for applying these drugs in clinical studies and neurological practice.
- Discusses recent findings in Abeta-42 immunization of transgenic rats as a potential disease-modifying therapy.
Impact:
- Provides an overview of established and experimental Alzheimer's disease therapies.
- Informs clinicians and researchers about current treatment standards and future directions.
- Suggests a paradigm shift towards disease-modifying treatments for Alzheimer's disease.